Vik serves as Head of Academic Partnerships at MiNA Therapeutics, where he leverages over 19 years of expertise in translational research to advance RNA activation (RNAa) therapeutics. A member of the company’s founding science team, he has dedicated over a decade to developing small activating RNAs (saRNAs), including MiNA’s first clinical candidate targeting CEBPA activation for therapeutic applications. Vik holds a BSc Honours in Molecular Genetics from Queen Mary University of London, an MSc in Cardiovascular Medicine from King’s College London, and a PhD in Oncology and Cancer Biology from Imperial College London. His work bridges academic innovation and industrial drug development, fostering strategic partnerships to accelerate breakthroughs in rare genetic diseases.